Apr 9, 2024 Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Mar 27, 2024 Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Mar 25, 2024 Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Mar 20, 2024 Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Dec 19, 2023 Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Dec 6, 2023 Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
